Compound comparison · Metabolic research

Tirzepatide vs Semaglutide

Tirzepatide targets two incretin receptors, while semaglutide targets GLP-1. Both have extensive clinical research histories, but a research vial is not the same as a regulated medicine.

Side-by-side research overview

Receptor targetsTirzepatideGLP-1 and GIPSemaglutideGLP-1
Research statusTirzepatideApproved medicines exist in some markets; research vials are not approved medicinesSemaglutideApproved medicines exist in some markets; research vials are not approved medicines
EvidenceTirzepatideSURMOUNT and SURPASS trial programmesSemaglutideSTEP and SELECT trial programmes

Do not compare outcomes across separate trials as if they were a head-to-head result. Trial populations, doses and follow-up periods differ. These catalogue items are for research only, not for human consumption or medical treatment.

Explore each compound

Questions about research vials?

Check the exact product, dosage and lot records before you order. Our team can confirm current availability and delivery for your Bali address.

Ask on WhatsApp